Results 101 to 110 of about 1,989,151 (330)

Inhibiting tryptophan metabolism enhances interferon therapy in kidney cancer. [PDF]

, 2016
Renal cell carcinoma (RCC) is increasing in incidence, and a complete cure remains elusive. While immune-checkpoint antibodies are promising, interferon-based immunotherapy has been disappointing.
Abu Aboud, Omran, Anderson, Katie, Berryhill, Grace, Chen, Ching-Hsien, Graef, Ashley, Hovey, Russell C, Kim, Jeffrey, Modiano, Jaime F, Sarver, Aaron L, Stewart, Benjamin, Trott, Josephine F, Uzal, Francisco, Weiss, Robert H, Wettersten, Hiromi   +13 more
core   +2 more sources

Role of Epigenetic Modifications in Inhibitory Immune Checkpoints in Cancer Development and Progression

Frontiers in Immunology, 2020
A balance between co-inhibitory and co-stimulatory signals in the tumor microenvironment (TME) is critical to suppress tumor development and progression, primarily via maintaining effective immunosurveillance.
Reem Saleh, S. Toor, V. Sasidharan Nair, E. Elkord   +3 more
semanticscholar   +1 more source

Reduced vascular leakage correlates with breast carcinoma T regulatory cell infiltration but not with metastatic propensity

Molecular Oncology, EarlyView.
A mouse model for vascular normalization and a human breast cancer cohort were studied to understand the relationship between vascular leakage and tumor immune suppression. For this, endothelial and immune cell RNAseq, staining for vascular function, and immune cell profiling were employed.
Liqun He, Chiara Testini, Neda Hekmati, Altea Bonello, Aglaia Schiza, Emmanuel Nwadozi, Mia Phillipson, Carina Strell, Michael Welsh   +8 more
wiley   +1 more source

Targeting Checkpoint Receptors and Molecules for Therapeutic Modulation of Natural Killer Cells

Frontiers in Immunology, 2018
Among the most promising therapeutic modalities for cancer treatment is the blockade of immune checkpoint pathways, which are frequently co-opted by tumors as a major mechanism of immune escape.
Nayoung Kim, Nayoung Kim, Hun Sik Kim, Hun Sik Kim, Hun Sik Kim   +4 more
doaj   +1 more source

Improving PARP inhibitor efficacy in bladder cancer without genetic BRCAness by combination with PLX51107

Molecular Oncology, EarlyView.
Clinical trials on PARP inhibitors in urothelial carcinoma (UC) showed limited efficacy and a lack of predictive biomarkers. We propose SLFN5, SLFN11, and OAS1 as UC‐specific response predictors. We suggest Talazoparib as the better PARP inhibitor for UC than Olaparib.
Jutta Schmitz, Anna L. Bartkowiak, Michael Rose, Nora Kolks, Patrick Petzsch, Vandana Solanki, Anne Stoffel, Bianca Faßbender, Leandra Lepping, Julka Volkamer, Karl Köhrer, Marc Seifert, Tokameh Mahmoudi, Tahlita C. M. Zuiverloon, Günter Niegisch, Michèle J. Hoffmann   +15 more
wiley   +1 more source

Targeting immune checkpoints in hematological malignancies

Journal of Hematology & Oncology, 2020
Immune checkpoint blockade (ICB) therapies such as anti-programmed death 1 (PD-1) and anti-CTLA-4 (cytotoxic T lymphocyte-associated protein 4) have dramatically transformed treatment in solid tumor oncology.
Basit Salik, Mark J. Smyth, Kyohei Nakamura   +2 more
doaj   +1 more source

Entwicklung und Validierung eines Bioassays zum Nachweis induzierter Genaktivität für den Einsatz auf der Internationalen Raumstation [PDF]

, 2007
Neben der fehlenden Schwerkraft stellt die Strahlenbelastung des Astronauten einen limitierenden Faktor für den Langzeitaufenthalt des Menschen im Weltraum dar.
Arenz, Andrea
core  

Accumulation of Self-Reactive Naive and Memory B Cell Reveals Sequential Defects in B Cell Tolerance Checkpoints in Sjogren's Syndrome [PDF]

, 2014
This work was funded by grants number 18237 and 20089 from Arthritis Research UK (http://www.arthritisresearchuk.org) to MB and the William Harvey Research Foundation.
A Cappione 3rd, A Hansen, A Hansen, A Hansen, A Hansen, A Kessel, B Chang, B Mietzner, C Vitali, Costantino Pitzalis, DI Stott, E Meffre, E Theander, Elisa Corsiero, F Barone, F Takemoto, H Mouquet, H Tsuboi, H Wardemann, IS Lossos, J Pijpe, J Samuels, Jay Reddy, JC Edwards, JF Scheid, JG Routsias, L Dawson, L Le Pottier, M Bombardieri, M Tsuiji, Michele Bombardieri, N Haneji, Nurhan Sutcliffe, P Youinou, S Salomonsson, S Yurasov, T Rogosch, T Tiller, T Tiller   +38 more
core   +3 more sources

Characterizing the molecular regulation of inhibitory immune checkpoints with multi-modal single-cell screens.

Nature Genetics, 2020
The expression of inhibitory immune checkpoint molecules, such as programmed death-ligand (PD-L)1, is frequently observed in human cancers and can lead to the suppression of T cell–mediated immune responses.
Efthymia Papalexi, Eleni P. Mimitou, Andrew Butler, Samantha Foster, Bernadette Bracken, William M. Mauck, H. Wessels, Y. Hao, Bertrand Z. Yeung, Peter Smibert, R. Satija   +10 more
semanticscholar   +1 more source

Cytoplasmic p21 promotes stemness of colon cancer cells via activation of the NFκB pathway

Molecular Oncology, EarlyView.
Cytoplasmic p21 promotes colorectal cancer stem cell (CSC) features by destabilizing the NFκB–IκB complex, activating NFκB signaling, and upregulating BCL‐xL and COX2. In contrast to nuclear p21, cytoplasmic p21 enhances spheroid formation and stemness transcription factor CD133.
Arnatchai Maiuthed, Kerstin Huebner, Katharina Erlenbach‐Wuensch, Chuanpit Hampel, Daniela Thalheim, Adriana Vial‐Roehe, Bodee Nutho, Susanne Merkel, Arndt Hartmann, Pithi Chanvorachote, Regine Schneider‐Stock   +10 more
wiley   +1 more source